Fibrinogen-Albumin Ratio: An Independent Recurrence Factor for Colorectal Cancer Stages II and III in a Competing Risk Model.

IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY
Journal of the Anus Rectum and Colon Pub Date : 2025-07-25 eCollection Date: 2025-01-01 DOI:10.23922/jarc.2024-112
Michiaki Shimada, Takanori Goi, Takayuki Tagai, Katsuzi Sawai, Mitsuhiro Morikawa, Masato Tamaki, Kenji Koneri
{"title":"Fibrinogen-Albumin Ratio: An Independent Recurrence Factor for Colorectal Cancer Stages II and III in a Competing Risk Model.","authors":"Michiaki Shimada, Takanori Goi, Takayuki Tagai, Katsuzi Sawai, Mitsuhiro Morikawa, Masato Tamaki, Kenji Koneri","doi":"10.23922/jarc.2024-112","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Colorectal cancer remains a major global health concern. Identifying high-risk patients is crucial for optimizing treatment strategies. The prognostic value of biomarkers, especially considering competing risks, remains unclear. We used a competing risks model to exclude the influence of non-cancer-related mortality and examined FAR as a predictor of recurrence in colorectal cancer.</p><p><strong>Methods: </strong>This retrospective study analyzed 359 patients with stage II or III colorectal cancer from the cecum to the oral side of the peritoneal inversion, all of whom underwent curative resection at Fukui University Hospital. The primary outcome was cancer recurrence. The fibrinogen-albumin ratio (FAR) was assessed using univariate and multivariate analyses, including competing risk models, with a cutoff value of >0.131.</p><p><strong>Results: </strong>Univariate analysis identified factors significantly associated with poorer outcomes, including T4 stage, gross appearance type 3/4/5 tumors, stage III disease, elevated neutrophil-to-lymphocyte ratio, prognostic nutritional index, carcinoembryonic antigen, and FAR. Multivariate analysis confirmed FAR as an independent prognostic factor. A predictive model combining FAR, stage III disease, and T4 stage demonstrated the best performance based on Akaike information criterion and Bayesian information criterion values.</p><p><strong>Conclusions: </strong>FAR is a robust prognostic biomarker for colorectal cancer. Incorporating FAR into clinical practice may enable healthcare providers to more accurately stratify high-risk patients, facilitating personalized treatment strategies.</p>","PeriodicalId":56349,"journal":{"name":"Journal of the Anus Rectum and Colon","volume":"9 3","pages":"321-329"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12307011/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Anus Rectum and Colon","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23922/jarc.2024-112","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Colorectal cancer remains a major global health concern. Identifying high-risk patients is crucial for optimizing treatment strategies. The prognostic value of biomarkers, especially considering competing risks, remains unclear. We used a competing risks model to exclude the influence of non-cancer-related mortality and examined FAR as a predictor of recurrence in colorectal cancer.

Methods: This retrospective study analyzed 359 patients with stage II or III colorectal cancer from the cecum to the oral side of the peritoneal inversion, all of whom underwent curative resection at Fukui University Hospital. The primary outcome was cancer recurrence. The fibrinogen-albumin ratio (FAR) was assessed using univariate and multivariate analyses, including competing risk models, with a cutoff value of >0.131.

Results: Univariate analysis identified factors significantly associated with poorer outcomes, including T4 stage, gross appearance type 3/4/5 tumors, stage III disease, elevated neutrophil-to-lymphocyte ratio, prognostic nutritional index, carcinoembryonic antigen, and FAR. Multivariate analysis confirmed FAR as an independent prognostic factor. A predictive model combining FAR, stage III disease, and T4 stage demonstrated the best performance based on Akaike information criterion and Bayesian information criterion values.

Conclusions: FAR is a robust prognostic biomarker for colorectal cancer. Incorporating FAR into clinical practice may enable healthcare providers to more accurately stratify high-risk patients, facilitating personalized treatment strategies.

Abstract Image

Abstract Image

纤维蛋白原-白蛋白比率:在竞争风险模型中结直肠癌II期和III期的独立复发因素。
目的:结直肠癌仍然是一个主要的全球健康问题。识别高危患者对于优化治疗策略至关重要。生物标志物的预后价值,特别是考虑到相互竞争的风险,仍然不清楚。我们使用竞争风险模型来排除非癌症相关死亡率的影响,并检验FAR作为结直肠癌复发的预测因子。方法:本回顾性研究分析了359例从盲肠到腹膜倒置口腔侧的II期或III期结直肠癌患者,所有患者均在福井大学医院行根治性切除术。主要终点是癌症复发。纤维蛋白原白蛋白比(FAR)采用单因素和多因素分析评估,包括竞争风险模型,截断值为bb0 0.131。结果:单因素分析确定了与预后不良显著相关的因素,包括T4期、大体外观类型3/4/5型肿瘤、III期疾病、中性粒细胞与淋巴细胞比值升高、预后营养指数、癌胚抗原和FAR。多因素分析证实FAR是一个独立的预后因素。基于赤池信息准则和贝叶斯信息准则值,结合FAR、III期和T4期的预测模型表现最佳。结论:FAR是一种可靠的结直肠癌预后生物标志物。将FAR纳入临床实践可以使医疗保健提供者更准确地对高危患者进行分层,促进个性化治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of the Anus Rectum and Colon
Journal of the Anus Rectum and Colon GASTROENTEROLOGY & HEPATOLOGY-
自引率
7.10%
发文量
37
审稿时长
18 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书